Preparations Characterized By Special Physical Form Patents (Class 424/400)
  • Patent number: 10289280
    Abstract: A device for programming an implantable fluid delivery device receives a therapeutic agent concentration, wherein the therapeutic agent concentration comprises a mass of the therapeutic agent per unit of volume. The device further determines a reference rate value based on the received therapeutic agent concentration, wherein the reference rate value comprises a mass per unit of time. The device additionally displays a graphical user interface comprising a horizontal axis and a vertical axis, wherein the horizontal axis represents time and the vertical axis represents rates of delivery of the fluid by the implantable fluid delivery device. The maximum value of the vertical axis displayed in the graphical user interface is determined based on the determined reference rate value and is determined to be less than a maximum therapeutic agent infusion rate.
    Type: Grant
    Filed: June 7, 2013
    Date of Patent: May 14, 2019
    Assignee: Medtronic, Inc.
    Inventors: Ajinkya M. Joglekar, Bradley C. Peck
  • Patent number: 10279012
    Abstract: Methods for delivering an effective amount of insulin to the central nervous system to treat Social Communication Disorder while minimizing systemic exposure to the administered insulin. The present invention provides these advantages by administering at least an effective amount of insulin and/or pharmaceutical composition(s) thereof, to the upper third of the nasal cavity, thereby bypassing the blood-brain barrier and delivering an effective amount of insulin and/or pharmaceutical compound(s) thereof directly to the CNS. Further methods comprise administering an at least an effective amount of therapeutic agents to the amniotic fluid surrounding a fetus with a treatable neurologic agent or a preventable neurologic condition. For example, administering the at least effective amount of insulin to the amniotic fluid of a fetus with a mother diagnosed with gestational diabetes may prevent the fetus from developing Social Communication Disorder or autism.
    Type: Grant
    Filed: March 10, 2014
    Date of Patent: May 7, 2019
    Assignee: HealthPartners Research & Education
    Inventor: William H. Frey, II
  • Patent number: 10274743
    Abstract: An imaging system includes an indicator installed around an antenna, wherein optical characteristics of the indicator change as a function of an electromagnetic field formed by the antenna, an imaging apparatus for imaging a change in optical characteristics of the indicator, a transmitter for radiating radio waves toward the antenna, and a receiver for receiving a signal from the antenna.
    Type: Grant
    Filed: December 20, 2016
    Date of Patent: April 30, 2019
    Assignees: Hyundai Motor Company, Sogang University Research Foundation
    Inventors: Sang Heun Lee, Sung-Hoon Jeon, Hanju Lee, Hyun-Wook Jang, Kiejin Lee, Do-Suck Han
  • Patent number: 10265262
    Abstract: A thickened aqueous composition containing about 0.01% to about 10%, by weight, of an superabsorbent polymer, about 0.1% to about 20%, of a silicone elastomer; about 0.1% to about 20%, by weight, of a fatty alcohol; and from about 20% to about 98% of water.
    Type: Grant
    Filed: September 21, 2017
    Date of Patent: April 23, 2019
    Assignee: The Procter & Gamble Company
    Inventors: Paul Robert Tanner, Mridula Manohar
  • Patent number: 10265396
    Abstract: Methods of making and using a magnetic ECM are disclosed. The ECM comprises positively and negatively charged nanoparticles, wherein one of said nanoparticles contains a magnetically responsive element. When the magnetic ECM is seeded with cells, the cells will be magnetized and can be levitated for 3-D cell culture.
    Type: Grant
    Filed: September 18, 2017
    Date of Patent: April 23, 2019
    Assignee: Greiner Bio-One North America, Inc.
    Inventor: Glauco R. Souza
  • Patent number: 10265439
    Abstract: The present invention provides a temperature-responsive dual-gelling hydrogel comprising a plurality of hydrogel polymers and a polymer cross-linking moiety, wherein the LCST of the hydrogel polymers is less than 37° C., and the polymer cross-linking moiety is capable of chemically cross linking to the hydrogel polymers to form a polymer matrix.
    Type: Grant
    Filed: August 19, 2016
    Date of Patent: April 23, 2019
    Assignee: ARIZONA BOARD OF REGENTS ON BEHALF OF ARIZONA STATE UNIVERSITY
    Inventors: Mehdi Nikkhah, Brent Vernon
  • Patent number: 10258586
    Abstract: The present invention is directed to methods and compositions for the treatment of diverticulosis. It is more specifically directed to compositions including L-glutamine, its salts, or its derivatives, and uses of such compositions in the treatment of diverticulosis. In a method aspect, the present invention provides a method of treating diverticulosis. The method includes ingestion of 0.05 g/kg body weight to 10.0 g/kg body weight of L-glutamine, an L-glutamine salt or an L-glutamine derivative per day by a person who has diverticulosis.
    Type: Grant
    Filed: February 10, 2017
    Date of Patent: April 16, 2019
    Assignee: Emmanus Medical, Inc.
    Inventor: Yutaka Niihara
  • Patent number: 10245238
    Abstract: Provided is a composition for oral intake, which exhibits improved oral absorbability of curcumin and/or an analog thereof and can be produced conveniently and inexpensively. A complex of curcumin and/or an analog thereof and a water-soluble cellulose derivative is disclosed.
    Type: Grant
    Filed: May 14, 2015
    Date of Patent: April 2, 2019
    Assignees: THERAVALUES CORPORATION
    Inventors: Hirofumi Takeuchi, Kohei Tahara, Atsushi Imaizumi, Tsukasa Takahashi, Takato Matsui, Hitomi Ozawa
  • Patent number: 10245351
    Abstract: Hybrid hydrogels formed of a plurality of peptides that are capable of self-assembling into a hydrogel in an aqueous solution and a biocompatible polymer that is characterized by high swelling capability, high elasticity and low mechanical strength are disclosed, with exemplary hybrid hydrogels being formed of a plurality of aromatic dipeptides and hyaluronic acid. The hybrid hydrogels are characterized by controllable mechanical and biological properties which can be adjusted by controlling the concentration ratio of the peptides and the polymer, and which average the mechanical and biological properties of the peptides and the polymer. Processes of preparing the hydrogels and uses thereof in pharmaceutical, cosmetic or cosmeceutic applications such as tissue engineering and/or regeneration are further disclosed.
    Type: Grant
    Filed: March 20, 2017
    Date of Patent: April 2, 2019
    Assignee: Technology Innovation Momentum Fund (Israel) Limited Partnership
    Inventors: Moran Aviv, Ludmila Buzhansky, Shmuel Einav, Zvi Nevo, Ehud Gazit, Lihi Adler-Abramovich
  • Patent number: 10232011
    Abstract: The invention provides low-dose formulations of guanylate cyclase-C (“GCC”) agonist peptides and methods for their use. The formulations of the invention can be administered either alone or in combination with one or more additional therapeutic agents, preferably an inhibitor of cGMP-dependent phosphodiesterase or a laxative.
    Type: Grant
    Filed: March 19, 2018
    Date of Patent: March 19, 2019
    Assignee: SYNERGY PHARMACEUTICALS, INC.
    Inventors: Stephen Comiskey, Rong Feng, John Foss, Kunwar Shailubhai
  • Patent number: 10231903
    Abstract: The present disclosure relates to a system and process for manufacturing patient personalized pharmaceutical compositions using superimposed revolution and rotation movements for dispersing, milling, melting, and/or de-aerating, where these superimposed revolution and rotation movements can be carried out in a single device in a pharmacy setting.
    Type: Grant
    Filed: November 10, 2017
    Date of Patent: March 19, 2019
    Assignee: MEDISCA PHARMACEUTIQUE INC.
    Inventors: Panagiota Danopoulos, Sarah Nyat Peng Wong, Vargha Talebi, Patrick-Martin Bader, Marc Joiner
  • Patent number: 10226426
    Abstract: The present invention provides a method of producing a suspension containing a nano-cocrystal having an average particle size of not more than 300 nm, a polymer having a number average molecular weight of not less than 3,000, a surfactant having a number average molecular weight of less than 3,000 and water, which method including wet grinding a cocrystal, which is constituted of an organic compound and a cocrystal former and is not dissociated by wet grinding, in water containing the polymer and the surfactant.
    Type: Grant
    Filed: March 1, 2016
    Date of Patent: March 12, 2019
    Assignee: Takeda Pharmaceutical Company Limited
    Inventors: Masatoshi Karashima, Katsuhiko Yamamoto, Takashi Kojima, Yukihiro Ikeda
  • Patent number: 10220067
    Abstract: The invention provides a method for extracting active therapeutic components from plant materials of the Cyclanthera pedata plant which comprises immersing said plant material containing active components and selected from the group consisting of fruits, flowers, leaves, stems, twigs, bark, wood, buds, seeds, roots, and pods in a solvent for a period of time of about 30 minutes to about 10 hours to achieve transfer of active components from the plant material to the solvent, separating the solvent containing active components from the plant material, and evaporating or distilling the solvent to produce a concentrated fraction containing active components. The invention further includes compositions and therapeutic formulations of such extracts to treat hypercholesterolemia and other high lipid related diseases.
    Type: Grant
    Filed: November 25, 2016
    Date of Patent: March 5, 2019
    Assignee: PROCAPS SA
    Inventors: Alejandro Mario Díaz Rebolledo, Carlos Perez Rebolledo
  • Patent number: 10213380
    Abstract: The present invention relates generally to a methods of treating ear infections and clearing excess fluid from Eustachian tubes.
    Type: Grant
    Filed: May 23, 2016
    Date of Patent: February 26, 2019
    Assignee: Try This First, Inc.
    Inventor: Scott Morehouse
  • Patent number: 10213524
    Abstract: The present invention relates to a coating, a substrate, a method for coating a body and a method for producing the body substrate, such as a dental or a bone implant. The coating has a high degree of mechanical stability and comprises elements, such as Sr based compounds, which optimize the tissue response to the implanted body thus stimulating healing, bone or tissue growth in the vicinity of the implant. An implant coated with this coating has the ability of sustained release of strontium in a non-toxic concentration of strontium in the vicinity of the implant.
    Type: Grant
    Filed: March 22, 2013
    Date of Patent: February 26, 2019
    Assignee: Elos Medtech Pinol A/S
    Inventors: Morten Foss, Ole Zoffmann Andersen, Michael Brammer Sillassen, Jørgen Bøttiger, Inge Hald Andersen, Klaus Pagh Almtoft, Lars Pleth Nielsen, Christian Schärfe Thomsen
  • Patent number: 10206932
    Abstract: Pharmaceutical compositions for co-administering estradiol and progesterone to a human subject in need thereof are provided. In some embodiments, the pharmaceutical composition comprises solubilized estradiol, suspended progesterone, and a solubilizing agent comprising a medium chain (C6-C12) oil.
    Type: Grant
    Filed: May 22, 2015
    Date of Patent: February 19, 2019
    Assignee: TherapeuticsMD, Inc.
    Inventors: Brian A. Bernick, Peter H. R. Persicaner, Julia M. Amadio
  • Patent number: 10206875
    Abstract: A composition of an omega-3 polyunsaturated fatty acid (PUFA)-taxoid conjugate encapsulated in an oil-in-water nanoemulsion (NE) drug delivery system. A method of treating cancer by administering an effective amount of a pharmaceutical composition including a PUFA-taxoid conjugate encapsulated in an oil-in-water NE drug delivery system to a subject in need of treatment, and treating cancer. A method of overcoming multidrug resistance by exposing a multidrug resistant cell to an effective amount of a pharmaceutical composition including an omega-3 polyunsaturated fatty acid (PUFA)-taxoid conjugate encapsulated in an oil-in-water NE drug delivery system, and inducing the death of the multidrug resistant cell. A method of eliminating a cancer stem cell. Methods of reducing stemness of a cancer stem cell, retaining drug in the body, and providing a slower release profile.
    Type: Grant
    Filed: June 7, 2017
    Date of Patent: February 19, 2019
    Assignees: TargaGenix, Inc., The Research Foundation for the State University New York, Northeastern University
    Inventors: James E. Egan, Iwao Ojima, Mansoor M. Amiji, Galina Ivanovna Botchkina
  • Patent number: 10208306
    Abstract: This disclosure relates to methods for promoting bone formation or reducing bone destruction. This disclosure also relates to methods for promoting the recruitment of mesenchymal stem cells (MSC) to a local site of injury or surgical intervention in bone to promote healing. In addition, this disclosure relates to methods for reducing or preventing mineral formation or bone growth, or reducing bone mass. The methods disclosed herein are useful for treating conditions such as osteoradionecrosis.
    Type: Grant
    Filed: May 28, 2015
    Date of Patent: February 19, 2019
    Assignee: The Research Foundation for the State University of New York
    Inventors: Nikhil A. Thakur, Bryan S. Margulies
  • Patent number: 10208287
    Abstract: An object of the present invention is to provide a myocardial progenitor cell that is specifically induced to differentiate into a cardiomyocyte, and a method for preparing the myocardial progenitor cell. A method for preparing a CD82-positive cell includes, in sequence, a step (a) of obtaining stem cells, a step (b) of subjecting the stem cells to induction treatment of differentiation into cardiovascular cells, and a step (c) of separating, from the stem cells having been subjected to the induction treatment of differentiation in the step (b), a CD82-positive cell being negative for at least one cell surface marker selected from CD73, CD44, CD105, CD121a, CD18, and CD120a. This method enables preparation of a CD82-positive cell for use as a myocardial progenitor cell.
    Type: Grant
    Filed: April 16, 2015
    Date of Patent: February 19, 2019
    Assignee: iHeart Japan Corporation
    Inventors: Jun Yamashita, Masafumi Takeda
  • Patent number: 10201506
    Abstract: The present invention is directed to particles prepared via the polymerization of at least one surfactant and an isocyanate-containing compound. Pharmaceutical compositions prepared using these particles are also described.
    Type: Grant
    Filed: February 6, 2017
    Date of Patent: February 12, 2019
    Assignee: CEPHALON, INC.
    Inventors: Peter D. Brown, Anthony S. Drager
  • Patent number: 10201457
    Abstract: Embodiments of the invention include wound packing devices and methods of making and using the same. In an embodiment, the invention includes a wound packing device including a plurality of spacing elements comprising a nanotextured surface. The wound packing device can also include a connector connecting the plurality of spacing elements to one another. Other embodiments are also included herein.
    Type: Grant
    Filed: July 30, 2015
    Date of Patent: February 12, 2019
    Assignee: Surmodics, Inc.
    Inventors: Gary Maharaj, Teryl L. Woodwick Sides
  • Patent number: 10201583
    Abstract: A supplement including a blend of turmeric, quercetin and rosemary, or holy basil, wasabi, and broccoli seed extract which are present in a balanced and predetermined ratio, and which stimulate the Antioxidant Response Element (ARE), Quinone Reductase, and/or induce related gene expression, for example, heme oxygenase-1 (HMOX-1) expression. The blend of ingredients can be formed as or in a dietary supplement adapted for administration to a subject. The dietary supplement can be formulated so that the turmeric, quercetin and rosemary are present in a predetermined ratio of 1:3:5, or holy basil, wasabi, and broccoli seed extract in a predetermined ratio of 1:1:0.2. Additional ingredients can be included in the supplement. The supplement can synergistically affect natural antioxidant response pathways within cells of a subject to whom the supplement is administered. A related method of use is also provided.
    Type: Grant
    Filed: November 3, 2016
    Date of Patent: February 12, 2019
    Assignee: Access Business Group International LLC
    Inventors: David J. Fast, Jennifer Patterson, Arun Rajgopal, Donald J. Pusateri, Kevin W. Gellenbeck, Jeffrey Scholten, Stephen R. Missler, Russell K. Randolph, Jennifer Chuang, Yumei Lin, Valiantsina Kazlova
  • Patent number: 10202333
    Abstract: The present invention provides a method of producing an aqueous solution containing bis(N?-lauroyl lysine)dicarboxylic acid diamide and/or a salt thereof, and having a pH of 9-11, which includes a first step of reacting N?-lauroyl lysine and/or a salt thereof with dicarboxylic acid dichloride in a water solvent having a pH of 12-14 to form bis(N?-lauroyl lysine)dicarboxylic acid diamide and/or a salt thereof, a second step of adjusting the aqueous solution obtained in the first step to pH 7.5-8.5, a third step of adding N?-lauroyl lysine to the aqueous solution obtained in the second step and filtering the mixture, and a fourth step of adjusting the aqueous solution obtained in the third step to pH 9-11.
    Type: Grant
    Filed: April 6, 2017
    Date of Patent: February 12, 2019
    Assignee: AJINOMOTO CO., INC.
    Inventor: Shun Kobayashi
  • Patent number: 10196389
    Abstract: Provided are a class of pyrazolone compounds and a use thereof. In particular, a compound represented by formula I is provided, wherein the definition of each variable group is as described in the description. The compounds of formula (I) have a direct AMPK-activating activity and can significantly promote the phosphorylation of AMPK and ACC of L6 myocytes and HepG2 cells in a dose-dependent manner.
    Type: Grant
    Filed: July 14, 2015
    Date of Patent: February 5, 2019
    Assignee: SHANGHAI INSTITUTE OF MATERIA MEDICA, CHINESE ACADEMY OF SCIENCES
    Inventors: Fajun Nan, Jia Li, Jingya Li, Mei Zhang, Dakai Chen, Lina Zhang, Runtao Zhang, Zhifu Xie
  • Patent number: 10195206
    Abstract: The present invention is directed to a pharmaceutical composition that includes a combination of about 2-5 milligrams of a non-steroidal anti-inflammatory drug and from about 2-30 milligrams of an opioid analgesic in a single pharmaceutical dosage unit that can provide effective chronic pain management with the added benefit of reduced side effects such as withdrawal and gastrointestinal disorders. The non-steroidal anti-inflammatory drug may be piroxicam and the opioid analgesic may be buprenorphine. The present invention also provides for a method of managing pain in a patient that includes administering the pharmaceutical composition previously described. The pharmaceutical composition previously described may be administered in a single or multiple dosage regimens.
    Type: Grant
    Filed: April 2, 2013
    Date of Patent: February 5, 2019
    Assignee: BRIDGE THERAPEUTICS, LLC
    Inventors: Alton Samuel Kelley, II, James Gregory Sullivan
  • Patent number: 10188626
    Abstract: Disclosed herein are improved formulations for the cabazitaxel. The formulations exhibit increased storage stability relative to other formulations, and are simpler for health care providers to prepare and administer to patients.
    Type: Grant
    Filed: November 3, 2016
    Date of Patent: January 29, 2019
    Assignee: Cipla Limited
    Inventors: Geena Malhotra, Sarabjit Singh, Ravichandra Bhadravathi Vedamurthy, Anirban Mallik Thakur, Dhiraj Abhyankar
  • Patent number: 10188753
    Abstract: A nanosensor-containing polymer composition for the monitoring of physiological parameters and a method for making the composition are disclosed. The composition includes a nanosensor disposed in a crosslinked, hydrophilic polymer for transdermal application into an intradermal environment. The method involves forming a mixture including nanosensors and a crosslinked polymer precursor, and subjecting the mixture to conditions suitable for crosslinking the polymer precursor to provide a nanosensor-containing crosslinked polymer.
    Type: Grant
    Filed: July 14, 2016
    Date of Patent: January 29, 2019
    Assignee: Verily Life Sciences LLC
    Inventors: Timothy Ruckh, Kimberly Kam
  • Patent number: 10188772
    Abstract: A medical device that releases a pharmaceutical agent to a target site is disclosed. The medical device includes a balloon, and a coating on at least a portion of the balloon. The coating includes particles of a pharmaceutical agent. Each particle of the particles of the pharmaceutical agent is at least partially encapsulated in a polymer material. A method of releasing a pharmaceutical agent at a target site is also disclosed. The method includes the steps of providing a device including a balloon, and a coating on at least a portion of the balloon, the coating including particles of a pharmaceutical agent, and each particle of the pharmaceutical agent is at least partially encapsulated in a polymer material; positioning the device to allow the balloon to reach the target site; and inflating the balloon of the device.
    Type: Grant
    Filed: October 18, 2013
    Date of Patent: January 29, 2019
    Assignee: Micell Technologies, Inc.
    Inventors: James B. McClain, Charles Douglas Taylor, Meagan M. Fagan
  • Patent number: 10188597
    Abstract: A hair color stain remover formula, having by volume about 67.9999% Witch Hazel Extract; about 20.0% Glycerin; about 8.8% Distilled Water; about 3.0% Sodium Cocoyl Glycinate; about 0.1% Potassium Sorbate; about 0.1% Sodium Benzoate; and about 0.0001% Green Tea Extract.
    Type: Grant
    Filed: February 28, 2018
    Date of Patent: January 29, 2019
    Inventor: Kamakshi Kata
  • Patent number: 10188594
    Abstract: The present invention relates to a fermented vegetable oil, to a method for preparing the oil, and to a composition including the oil. More particularly, the present invention relates to a technique for providing a fermented vegetable oil having the effects of enhancing emulsion stability due to water retention ability, improving texture and flavor, and enhancing moisturization.
    Type: Grant
    Filed: May 6, 2016
    Date of Patent: January 29, 2019
    Assignees: DAMY CHEMICAL CO., LTD., KOREA RESEARCH INSTITUTE OF BIOSCIENCE AND BIOTECHNOLOGY
    Inventors: Kwang-Nyeon Kim, Ju-Hyun Son, Hee-Sik Kim, Jong-Seok Yun
  • Patent number: 10183077
    Abstract: An iron-based composition is described. The composition can be used in conditions of total or relative iron deficiency. In particular, a solid composition is described, preferably in the form of powder or granules, for use in the treatment of disorders or diseases related to or derived from an iron deficiency. The composition is suitable for pediatric subjects, adolescents, athletes, men, women, pregnant women and elderly. Finally, a process for preparing the solid composition is also described.
    Type: Grant
    Filed: July 30, 2013
    Date of Patent: January 22, 2019
    Assignee: ALESCO S.R.L.
    Inventors: Andrea Lacorte, Germano Tarantino
  • Patent number: 10179072
    Abstract: A wound care bandage for treating a wound is provided. The bandage includes an SIS layer to be placed on the wound surface and a cover to be placed over the wound. The bandage further includes a structure to provide a vacuum space. A method for promoting wound healing is further provided. The method includes applying the above-mentioned wound care bandage to the wound and creating a vacuum in the vacuum space to draw blood controllably from the wound into the SIS layer.
    Type: Grant
    Filed: February 8, 2018
    Date of Patent: January 15, 2019
    Assignee: KCI Medical Resources Unlimited Company
    Inventor: Arthur C. Coffey
  • Patent number: 10174292
    Abstract: The present application relates to novel HIV-1 envelope glycoproteins which may be utilized as an HIV-1 vaccine immunogens, antigens for crystallization and for the identification of broad neutralizing antibodies. The present invention encompasses the preparation and purification of immunogenic compositions which are formulated into the vaccines of the present invention.
    Type: Grant
    Filed: March 21, 2016
    Date of Patent: January 8, 2019
    Assignees: International AIDS Vaccine Initiative, The Scripps Research Institute
    Inventors: Viktoriya Dubrovskaya, Francisco Javier Guenaga, Richard Wyatt
  • Patent number: 10172775
    Abstract: The present invention is directed to combination sunscreen and insect repellant compositions. The combination sunscreen and insect repellant compositions contain (i) diethyl toluamide (or N,N-Diethyl-3-methylbenzamide or DEET), (ii) one or more sunscreen components, with each sunscreen component being capable of absorbing ultraviolet light rays, and (iii) a polymeric binder system. The combination sunscreen and insect repellant compositions may contain additional composition components such as butyloctyl salicylate, a crosslinked polyacrylate polymer, and deionized water. The present invention is also directed to methods of making and using combination sunscreen and insect repellant compositions.
    Type: Grant
    Filed: March 28, 2017
    Date of Patent: January 8, 2019
    Assignee: Sunsect, Inc.
    Inventor: Jerry Steven Johnson
  • Patent number: 10172810
    Abstract: Disclosed are preparations and formulations of high thermodynamic activity lipophilic associations (LA), in which there is pairing between an ionizable pharmaceutical agent and a lipophilic species having ionic characteristics opposite to that of the pharmaceutical agent. Such lipophilic associations manifest high thermodynamic activity, as evidenced by their being predominantly in a liquid phase at room temperature or solvated in a lower-than-water dielectric solvent. Further the pharmaceutical agent being solubilized means that dissolution is not rate limiting to transmucosal absorption. This LA or LA-solvate is formulated into a low dielectric dosage form, from when, upon the dosage form's hydration, the pharmaceutical agent is driven through the mucosal tissue and into systemic circulation. The invention therefore provides an enhanced transmucosal drug delivery system for ionizable pharmaceutical agents at or near physiological pH.
    Type: Grant
    Filed: May 6, 2016
    Date of Patent: January 8, 2019
    Assignee: Pharmaceutical Productions, Inc.
    Inventor: John A. McCarty
  • Patent number: 10159687
    Abstract: The disclosure relates to prodrugs of vitamin K2, in particular prodrugs of MK-7 in which the diketone is converted to a monosubstituted or disubstituted ester type derivative. These compounds are shown to give MK-7 in plasma. The disclosure also relates to methods of treating conditions using prodrugs of vitamin K2.
    Type: Grant
    Filed: December 5, 2016
    Date of Patent: December 25, 2018
    Assignee: KAPPA BIOSCIENCE AS
    Inventors: Mona Moller, Marcel Sandberg, Inger Reidun Aukrust
  • Patent number: 10161013
    Abstract: The present invention discloses a method for isolating and purifying anhydrogalactose. Using the method for isolating and purifying anhydrogalactose including the steps of preparing a sugar mixture containing anhydrogalactose produced through chemical synthesis and hydrolysis; and isolating anhydrogalactose by performing recycling preparative liquid chromatography (recycling-prep-LC) with the sugar mixture, highly pure anhydrogalactose can be efficiently isolated and purified in large amounts.
    Type: Grant
    Filed: January 22, 2016
    Date of Patent: December 25, 2018
    Assignee: Biol Systems Co., Ltd.
    Inventors: Dongjoong Im, Gyungsoo Kim
  • Patent number: 10154975
    Abstract: The present specification discloses pharmaceutical compositions, methods of preparing such pharmaceutical compositions, and methods and uses of treating a chronic inflammation and/or an inflammatory disease in an individual using such pharmaceutical compositions.
    Type: Grant
    Filed: October 26, 2017
    Date of Patent: December 18, 2018
    Assignee: Infirst Healthcare Limited
    Inventors: Robin M. Bannister, John Brew, Richard R. Reiley, III, Wilson Caparros Wanderley
  • Patent number: 10155869
    Abstract: The invention concerns a compound formed by functionalized micro- or nanoparticles associated covalently with rheology-modifying polymers. The invention is characterized in that the functionalized micro- or nanoparticles are functionalized micro- or nanoparticles of cerium oxide (CeO2) having a nominal diameter of between 1 and 1500 nm. The rheology-adapting or -modifying polymers are selected from among non-associative or associative polymers. The invention is used in skin protection or decontamination.
    Type: Grant
    Filed: July 18, 2014
    Date of Patent: December 18, 2018
    Assignees: UNIVERSITE NICE SOPHIA ANTIPOLIS, CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE, UNIVERSITE D'ORLEANS
    Inventors: Sonia Amigoni, Denis Josse, Thierry Devers, Arnaud Zenerino, Frédéric Guittard, Elisabeth Taffin de Givenchy, Cécile Bignon
  • Patent number: 10143674
    Abstract: Described herein are compositions that include an aqueous phase and 5 to 30%, by weight, of an oil phase, based on the total weight of the composition. The oil phase comprises the omega-3 fatty acid triglyceride eicosapentaenoic acid triglyceride, docosahexaenoic acid triglyceride, or mixtures thereof. The composition further comprises at least one amphoteric surfactant, at least one co-surfactant, and at least one co-solvent. The compositions comprise less than 0.03% by weight of sodium oleate, based on the total weight of the composition. Also described are methods for preparing such compositions as well as such compositions for use as a medicament, in particular for use in treating stroke, sepsis, Alzheimer's disease or cancer. Also featured are methods of treating these conditions by parenterally administering a composition to a patient in need and methods of providing parenteral nutrition to such patients by administering to them a composition as described herein.
    Type: Grant
    Filed: January 28, 2015
    Date of Patent: December 4, 2018
    Assignee: FRESENIUS KABI DEUTSCHLAND GMBH
    Inventors: Edmundo Brito De La Fuente, Crispulo Gallegos-Montes, Lida A. Quinchia-Bustamente
  • Patent number: 10137172
    Abstract: The invention relates to a novel administration regime useful in the treatment of diseases or conditions where administration of insulin will be of benefit, as well as to kits for use in the same. In particular, the invention relates to a long-acting or ultra-long acting insulin for use in treating a disease or condition where administration of insulin will be of benefit, wherein the administration of said insulin comprises or consists of the following steps: (a) optionally providing a blood sample to be tested from an individual in need of treatment; (b) taking a single fasting blood (or plasma) glucose measurement from said individual in need of treatment; (c) using the single fasting blood (or plasma) glucose measurement to determine the insulin dose to be administered; and (d) administering the long-acting or ultra-long insulin to the individual at the dose determined in step (c).
    Type: Grant
    Filed: April 30, 2014
    Date of Patent: November 27, 2018
    Assignee: Novo Nordisk A/S
    Inventors: Thue Johansen, Ann Marie Ocampo Francisco, Torsten Christensen, Jens Harald Kongsoe, Trine Ahlgreen
  • Patent number: 10132037
    Abstract: The present invention relates to sizing agent formulations, especially to stabilizing a sizing formulation by a modified non-food polysaccharide. The method for preparation of the modified non-food polysaccharide is further provided.
    Type: Grant
    Filed: February 6, 2015
    Date of Patent: November 20, 2018
    Assignee: Kemira Oyj
    Inventors: Reetta Strengell, Juha Lindfors, Sari Hyvärinen, Sauli Vuoti
  • Patent number: 10132038
    Abstract: The present invention is related to sizing agent formulations, especially to stabilizing a sizing formulation by a modified non-food polysaccharide. The method for preparation of the modified non-food polysaccharide is further provided.
    Type: Grant
    Filed: February 6, 2015
    Date of Patent: November 20, 2018
    Assignee: Kemira Oyj
    Inventors: Reetta Strengell, Juha Lindfors, Sari Hyvärinen, Sauli Vuoti
  • Patent number: 10124051
    Abstract: The invention provides a conjugate of a Neisseria meningitidis serogroup X capsular polysaccharide and a carrier molecule. The conjugate is typically made by (a) oxidizing a primary hydroxyl group in the capsular polysaccharide, to give an oxidized polysaccharide with an aldehyde group; and (b) coupling the oxidized polysaccharide to a carrier molecule via the aldehyde group, thereby giving the conjugate. The conjugate may be part of an immunogenic composition. This composition may comprise one or more further antigens, particularly capsular polysaccharides from serogroups A, W135, C and Y and conjugated forms thereof. The composition may be in an aqueous formulation. The composition is useful as a vaccine, e.g. for raising an immune response in a mammal. The invention also provides processes for making the conjugate.
    Type: Grant
    Filed: May 22, 2013
    Date of Patent: November 13, 2018
    Assignee: GLAXOSMITHKLINE BIOLOGICALS SA
    Inventors: Maria Rosaria Romano, Francesca Micoli, Francesco Berti, Roberto Adamo, Paolo Costantino
  • Patent number: 10117967
    Abstract: The embodiments herein disclose a method of fabricating composite scaffolds for skin tissue regeneration. The methacrylated hyaluronic acid (HAMA) and methacrylated gelatin (GelMA) are synthesized. The poly (glycerol sebacate)-poly(?-caprolactone) (PGS-PCL) microfibrous scaffolds are synthesized. The hydrogel is synthesized. The composite scaffold comprising hydrogel and poly (glycerol sebacate)-poly(?-caprolactone) (PGS-PCL) microfibrous scaffolds is fabricated. A plurality of physico-chemical characteristics of the composite scaffold comprising hydrogel and poly (glycerol sebacate)-poly(?-caprolactone) (PGS-PCL) microfibrous scaffolds are analysed. The physico-chemical characteristics comprises mechanical properties, swelling ratio and enzymatic degradation and scanning electron microscope imaging. The fibroblast cells are encapsulated within the composite scaffold comprising hydrogel and poly (glycerol sebacate)-poly(?-caprolactone) (PGS-PCL) microfibrous scaffolds and hydrogels.
    Type: Grant
    Filed: October 11, 2017
    Date of Patent: November 6, 2018
    Inventors: Maryam Eslami, Parvaneh Reshteh Ahmadi, Alireza Eslami
  • Patent number: 10117818
    Abstract: The present invention relates to a wet wipe concentrate composition which may be blended with water or another solvent to form an impregnating formulation for a wet wipe. The present invention also relates to said wet wipe impregnating formulation and a wet wipe containing said formulation.
    Type: Grant
    Filed: August 15, 2016
    Date of Patent: November 6, 2018
    Assignee: ARCH PERSONAL CARE PRODUCTS, LP
    Inventors: Khat Kevin Lou, Mark Garrison, Joseph Librizzi
  • Patent number: 10117829
    Abstract: The subject invention provides improved diclofenac gel formulations.
    Type: Grant
    Filed: May 18, 2018
    Date of Patent: November 6, 2018
    Assignee: Ferring B.V.
    Inventors: Arnaud Grenier, Dario N. Carrara
  • Patent number: 10117431
    Abstract: The invention is directed to methods and compositions for increasing a growth characteristic of a plant, increasing nutrient use efficiency of a plant, or improving a plant's ability to overcome stress comprising applying a composition comprising ketosuccinamate, a derivative thereof, or a salt thereof, to the plant or to a propagation material of the plant.
    Type: Grant
    Filed: August 1, 2016
    Date of Patent: November 6, 2018
    Assignees: Los Alamos National Security, LLC, University of Maine System Board of Trustees
    Inventors: Pat J. Unkefer, Thomas Joseph Knight
  • Patent number: 10118901
    Abstract: The present invention relates to a class of hydroxamic acid compounds of Formula (I), which act as alkylating agents and/or inhibitors of the HDAC pathway, having potential utility in the treatment of a neoplastic disease and immune diseases.
    Type: Grant
    Filed: January 31, 2013
    Date of Patent: November 6, 2018
    Assignee: Purdue Pharmaceutical Products L.P.
    Inventors: Yu Chen, Yi Chen
  • Patent number: 10111980
    Abstract: Disclosed is a dry composition comprising one or more polyols, which upon addition of an aqueous medium forms a substantially homogenous paste suitable for use in haemostasis procedures. The paste reconstitutes spontaneously upon addition of the liquid; hence no mechanical mixing is required for said paste to form. The composition may further comprise an extrusion enhancer, such as albumin. Also disclosed are methods of preparing said dry composition, a paste obtained from said dry composition and uses of said dry composition or paste for medical and surgical purposes.
    Type: Grant
    Filed: December 10, 2014
    Date of Patent: October 30, 2018
    Assignee: Ferrosan Medical Devices A/S
    Inventor: Kristian Larsen